Dr. Vijay Kumar Prajapati

Contact Info
Dr. Vijay Kumar Prajapati
Dr. Vijay Kumar Prajapati

Associate Professor

Department of Biochemistry

School of Basic Sciences

Qualification

Ph.D. in Biochemistry from Institute of Medical Sciences, Banaras Hindu University in 2012

M.Sc. in Biochemistry from Banaras Hindu University in 2006

B.Sc. (Hons.) in Chemistry from Banaras Hindu University in 2004

Experience
Teaching Experience

Assistant Professor- Department of Biochemistry, Central University of Rajasthan, Aug 2013- Dec 2022

 
Research Experience

Postdoctoral Fellow- Mitchell Cancer Institute, University of  South Alabama, USA  Nov 2012- June 2013

Scientist- Department of Medicine, IMS BHU, Varanasi, Dec 2011- Nov 2012

 
Administrative Experience
 
Any Other Experience

 

Research Area

Infection Biology, Drug discovery and vaccine development, Bioinformatics

Research Grants/Projects
  1. UGC (2015-16) as Principal Investigator- Antileishmanial activity of silver nanoparticles attached to amphotericin B. (06 Lakhs)
  2. SERB-DST (2016-18) as Principal Investigator- Development of natural product derived febrifugine analogues as a novel therapeutics against Visceral Leishmaniasis (30 Lakhs)
  3.  DBT (2016-19) as mainland Co-PI- Molecular and Structural Characterization of Mitochondrial DNA Primase in Leishmania donovani. (119.51 Lakhs)
  4.  Chancellor’s Award for Best Faculty-2018, CURaj (03 Lakhs)
  5. DHR Young Scientist (2020-21) as Mentor- Mapping and Characterization of the genome-wide Toxin-Antitoxin loci of human pathogenHelicobacter pylori for their role in persistence (24.78 lakhs)
Professional Recognition/Awards/Scholarships
  • Malaviya Memorial Award (Young Faculty) 2022, The Biotech Research Society, India (BRSI)
  • Prof.Umakant Sinha Memorial Award 2019, Indian Science Congress Association
  • Chancellor’s Award for Best Faculty 2018- Central University of Rajasthan
  • AMI Young Scientist Award 2018- Association of Microbiology of India.
  • First Prize in the contest of Young Scientist at the conference “Perspective technologies in Vaccination &Immunotehrapy” at Moscow, Russia; October 2018.
  • ISCB Young Scientist Award 2018- Indian Society of Chemists & Biologists.
  • Young Scientist Award 2017- National Academy of Agricultural Sciences, New Delhi.
  • Associate -2017, National Academy of Agricultural Sciences, New Delhi.
  • Young Scientist Award 2016- The Biotechnology Research Society, India (BRSI).
  • Represented CURaj in the Festival of Innovation at President House, New Delhi,March 2016.
  • Associate -2016, Indian Academy of Sciences, Bengaluru.
  • ASM-IUSSTF Indo-US Research Professorship-2016 from American Society for Microbiology (ASM) and Indo-US Science and Technology Forum (IUSSTF).
  • INSA Medal for Young Scientist-2015 in Health Sciences from INSA, New Delhi, India.
  • Shakuntla Amir Chand Prize 2014 from Indian Council of Medical Research, New Delhi.
  • MNASc, (Member, The National Academy of Sciences, India) May 2014. 
  • Best Speaker Award in Global Infectious Diseases 2013 at ICGEB, Cape Town, South Africa.
  • Ranbaxy Science Scholar Award-2011 from Ranbaxy Science Foundation, Gurgaon, India.
  • WHO award to attend “Advanced WHO-IRTC/UNIL Course on Immunology, Vaccinology and Biotechnology applied to Leishmania” at the University of Lausanne, Switzerland, October 2011.
  • Certificate of Merit from Nanoscience and Technology Unit, BHU for R&D effort on Nanomedicine drug delivery on the occasion of India Independence day, August 2010.
  • European Commission fellowship for six-week internship with Prof. Jean-Claude Dujardin in the Institute of Tropical Medicine, Antwerp, Belgium, April-May 2009.
Publications
Papers
 
Articles
  1. Singh S, Rao A, Kumar K, Mishra A, Prajapati VK*; Translational vaccinomics and structural filtration algorithm to device multiepitope vaccine for catastrophic monkeypox virus. Computers in Biology and Medicine, January 2023. DOI- 10.1016/j.compbiomed.2022.106497. (IF-6.698)
  2. Singh S, Chouhan P, Sharma V, Kumbhar BV, Prajapati VK*; Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection. Structural Chemistry, December 2022. DOI- 10.1007/s11224-022-02113-9. (IF-1.795)
  3. Panda M, Kalita E, Singh S, Kumar K, Prajapati VK*; Nanobody-Peptide-Conjugate (NPC) for passive immunotherapy against SARS-CoV-2 Variants of Concern (VOC): A Prospective Pan-Coronavirus Therapeutics. Molecular Diversity, November 2022,  doi: 10.1007/s11030-022-10570-x. (IF-3.364)
  4. Godara P, Naik B, Meghwal R, Ojha R, Srivastava V, Prajapati VK, Prusty D; Rational designing of peptide-ligand conjugates-based immunotherapy for the treatment of complicated malaria. Life Sciences. 2022 Oct 23;311(Pt A):121121. (IF-6.78)
  5. Mandal A, Hazra B, Prajapati VK, Moundipa PF; Plant Products for Antiviral Therapeutics. Frontiers in Pharmacology, 2022 Oct 17;13:1039183. (IF-5.988)
  6. ChouhanP, Singh S, Sharma V, Prajapati VK*; Anti-IL-10 antibody humanization by SDR grafting with enhanced affinity to neutralize the adverse response of interleukin-10. International Journal of Peptide Research and Therapeutics.28, 148 (2022). https://doi.org/10.1007/s10989-022-10456-4(IF-2.191)
  7. Singh S, Prajapati VK*; Exploring actinomycetes natural products to identify potential multi-target inhibitors against Leishmania donovani. 3 Biotech, 2022 Sep;12(9):235. (IF-2.893)
  8. Panda M, Kalita E, Singh S, Kumar K, Rao A, Prajapati VK*; MiRNA-SARS-CoV-2 Dialogue and Prospective Anti-COVID-19 Therapies. Life Sciences. July 2022. doi: 10.1016/j.lfs.2022.120761.(IF-6.78)
  9. Singh S, Kumar K, Panda M, Srivasatava A, Mishra A, Prajapati VK*; High throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases. Molecular Diversity, 2022 April. doi: 10.1007/s11030-022-10452-2. (IF-3.364)
  10. Pandey RK, Ojha R, Devender M, Sebastian P, Namdeo M, Kunbhar BV, Sundar S, Maurya RS, Prajapati VK*; Febrifuginedihydrochloride as a new oral chemotherapeutic agent against visceral leishmaniasis infection. Experimental Parasitology. 2022 May-Jun;236-237:108250. (IF-2.132)
  11. Ojha R, Gurjar K, Ratnakar TS, Mishra A,  Prajapati VK*;Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Human Immunology. April 2022. 8, 346–355.(IF-2.211)
  12. Gupta N, Behera DK, Prajapati VK, Verma VK; A comprehensive approach to discover Toxin-Antitoxin systems from human pathogen Helicobacter pylori: A poison and its antidote encapsulated in the genome. Life Sciences. 2021 Nov 26:120149. doi: 10.1016/j.lfs.2021.120149. (IF-6.78)
  13. Kumar BK, Faheem, Sekhar KVGC, Ojha R, Prajapati VK, Pai A, Murugesan S; Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. Journal of Biomolecular Structure and Dynamics. 2022 Feb;40(3):1363-1386.  (IF-5.235)
  14. Ojha R, Prajapati VK*; Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity. Journal of Cellular Physiology. 2021 Dec;236(12):8020-8034.  (IF-6.513)
  15. Kumar P, Jagtap YA, Patwa SM, Kinger S, Dubey AR, Prajapati VK, Dhiman R, Poluri KM, Mishra A; Autophagy based cellular physiological strategies target oncogenic progression. Journal of Cellular Physiology, 2022 Jan;237(1):258-277. (IF-6.513)
  16. Sundaria N, Upadhyay A, Prasad A, Prajapati VK, Poluri KM, Mishra A; Neurodegeneration & Imperfect Ageing: Technological Limitations and Challenges? Mechanisms of Ageing and Development. 2021 Sep 22:111574. doi: 10.1016/j.mad.2021.111574. (IF-5.498)
  17. Prusty D, Gupta N, Upadhyay A, Dar A, Naik B, Kumar N, Prajapati VK;  Asymptomatic malaria infection prevailing risks for human health and malaria elimination. Infection Genetics & Evolution. 2021 Jun 30;93:104987. (IF-4.393)
  18. Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P; Interleukin-17-A multifaceted cytokine in viral infections. Journal of Cellular Physiology. 2021 Dec;236(12):8000-8019. (IF-6.513)
  19. Naik B, Mattaparthi VSK, Gupta N, Ojha R, Das P, Singh S, Prajapati VK, Prusty D; Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications. Journal of Biomolecular Structure and Dynamics.2021 Jun 1:1-25. doi: 10.1080/07391102.2021.1931451. (IF-5.235)
  20. Rajput VS, Sharma R, Kumari A, Vyas N, Prajapati VK, Grover A; Engineering a multi epitope vaccine against SARS-CoV-2 by exploiting its non structural and structural proteins. Journal of Biomolecular Structure and Dynamics. 2021 May 26:1-18. doi: 10.1080/07391102.2021.1924265.(IF-5.235) 
  21. Upadhyay A, Amanullah A, Joshi V, Dhiman R, Prajapati VK, Poluri KM, Mishra A; Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases. Drug Metabolism Reviews. 2021 Feb;53(1):100-121. (IF-6.984)
  22. Kumar N, Admane N, Kumari A, Sood D, Grover S, Prajapati VK, Chandra R, Grover A; Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework. Scientific Reports. 2021 Apr 7;11(1):7653. doi: 10.1038/s41598-021-86986-6. (IF-4.996)
  23. Sharma V, Chouhan P, Pandey RK, Ojha R, Aathmanathan VS, Krishnan M, Prajapati VK*; Immunoglobulin interface redesigning to enhance lebrikizumab mediated immunomodulation of IL-13 hyper-response. Journal of Biomolecular Structure and Dynamics; 2021 Jul;39(11):4051-4065.(IF-5.235)
  24. Upadhyay A, Sundaria N, Dhiman R, Prajapati VK, Prasad A, Mishra A; Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. Neuroscientist. 2021 Feb 3:1073858421989582. doi: 10.1177/1073858421989582. (IF-7.235)
  25. Sirohi PR, Gupta J, Somvanshi P, Prajapati VK, Grover A; Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein. Journal of Biomolecular Structure and Dynamics. 2020 Nov 27:1-12. doi: 10.1080/07391102.2020.1846626.  (IF-5.235)
  26. Gupta N, Khatoon N, Mishra A, Verma VK, Prajapati VK*; Structural vaccinology approach to investigate the virulent and secretory proteins of Bacillus anthracis for devising anthrax next-generation vaccine. Journal of Biomolecular Structure and Dynamics; 2020 Oct;38(16):4895-4905.(IF-5.235)
  27. Ojha R, Gupta N, Naik B, Singh S, Verma VK, Prusty D, Prajapati VK*; High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19. European Journal of Pharmaceutical Sciences. 2020 Aug 1;151:105375. (IF- 5.112)
  28. Naik B, Gupta N, Ojha R, Singh S, Prajapati VK, Prusty D; High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. International Journal of Biological Macromolecules, 2020 May 26;160:1-17.  (IF- 8.025)
  29. Ojha R, Pandey RK, Prajapati VK*; Vaccinomics strategy to concoct a promising subunit vaccine for visceral leishmaniasis targeting sandfly and leishmania antigens. International Journal of Biological Macromolecules, 2020 Aug 1;156:548-557.  (IF- 8.025)
  30. Joshi V, Upadhyay A, Prajapati VK, Mishra A;How autophagy can restore proteostasis defects in multiple diseases? Medicinal Research Reviews, 2020 Jul;40(4):1385-1439. (IF-12.388)
  31. Pandey RK, Ojha R, Dipti K, Kumar R, Prajapati VK*; Immunoselective algorithm to devise multi-epitope subunit vaccine fighting against human cytomegalovirus infection. Infection, Genetics and Evolution. 2020 Mar 10;82:104282. (IF-4.393)
  32. Gupta N, Ragar H, Verma VK, Prusty D, Mishra A, Prajapati VK*; Receptor-ligand based molecular interaction to discover adjuvant for immune cell TLRs to develop next-generation vaccine. International Journal of Biological Macromolecules, 2020 Feb 26;152:535-545. (IF- 8.025)
  33. Rostamtabar M, Rahmani A, Baee M, Karkhah A, Prajapati VK, Ebrahimpour S, Nouri HR; Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitides using comprehensive immunoinformatics approach. Infection, Genetics and Evolution. 2019 Nov;75:103992. (IF-4.393)
  34. Veronica J, Sanbamurthy C, Alti D, Prajapati VK, Sundar S, Maurya R; Iron superoxide dismutase contributes for Miltefosine resistance in Leishmania donovani. FEBS Journal. 2019 Sep;286(17):3488-3503.. (IF- 5.622)
  35. Ojha R, Pareek A, Pandey RK, Prusty D, Prajapati VK*, Strategic development of a next-generation multi-epitope vaccine to prevent Nipah virus zoonotic infection. ACS Omega;  2019 Aug 7;4(8):13069-13079.(IF- 4.132)
  36. Mishra R, Upadhyay A, Prajapati VK, Dhiman R, Poluri KM, Jana NR, Mishra A; LRSAM1 E3 Ubiquitin Ligase: Molecular Neurobiological Perspectives Linked With Brain Diseases. Cellular and Molecular Life Sciences. 2019 Jun;76(11):2093-2110.  (IF- 9.207)
  37. Ojha R, Prajapati VK. MiR-20a loaded with nanoparticles helps in the reduction of colorectal liver metastasis. Non-coding RNA Investigation 2019;3:2. doi: 10.21037/ncri.2018.12.03.
  38. Pandey RK, Ojha R, ChaterjeeN,Upadhyay N, Mishra A, Prajapati VK*; Combinatorial screening algorithm to engineer multi-epitope subunit vaccine minimizing Human T-lymphotropic virus-1 infection. Journal of Cellular Physiology. 2019 Jun; 234(6):8717-8726.  (IF-6.513)
  39. Khatoon N, Pandey RK, Ojha R, Veeranarayanan SA, Krishnan M,Prajapati VK*; Exploratory algorithm to devise multi-epitope subunit vaccine by investigating Leishmania donovani membrane proteins. Journal of Biomolecular Structure and Dynamics; 2019 Jun;37(9):2381-2393.(IF-5.235)
  40. Ojha R, Nandani R, Prajapati VK*; Contriving multi-epitope subunit vaccine by exploiting structural and non-structural viral proteins to prevent Epstein Barr Virus associated malignancy. Journal of Cellular Physiology. 2019 May;234(5):6437-6448. (IF-6.513)
  41. Pandey RK, Dahiya S, Mahita J, Sowdhamini R, Prajapati VK*; Vaccination and immunization strategies to develop Aedesaegypti salivary protein-based subunit vaccine tackling Flavivirus infection. International Journal of Biological Macromolecules, 2019 Feb 1;122:1203-1211. (IF- 8.025)
  42. Ojha R, Nandani R, Pandey RK, Prajapati VK*; Emerging Role of Circulating miRNA in the Diagnosis of Human Infectious Diseases. Journal of Cellular Physiology. 2019 Feb;234(2):1030-1043. (IF-6.513)
  43. Pandey RK, Prajapati VK*; Exploring sand fly salivary proteins to design multi-epitope based subunit vaccine to fight against visceral leishmaniasis. Journal of Cellular Biochemistry;Feb2019;120 (2):1141‐1155.(IF-4.48)
  44. Validi M, Karkhah A, Prajapati VK, Nouri HR; Immuno-informatics based approaches to design a novel multi epitope-based vaccine for immune response reinforcement against Leptospirosis, Molecular Immunology. Dec 2018, 104; 128-138. (IF- 4.174)
  45. Azman NSN, Mahboob M, Hossan S, Prajapati VK, Pandey RK, Hazra B, Raju CS, Nissapatorn V, Rahmatullah M, Wiart C; Anti-infective activities of 11 plants species used in traditional medicine in Malaysia.Experimental Parasitology, 2018 Nov;194:67-78.  (IF-2.132)
  46. Khatoon N, Ojha R, Mishra A, Prajapati VK*; Examination of antigenic proteins of Trypanosoma cruzi to fabricate an epitope-based subunit vaccine by exploiting epitope mapping mechanism. Vaccine. 2018 Oct 8;36(42):6290-6300.  (IF-4.169)
  47. Renitta N, Thiyonila B, Aathmanathan V, Ramya T, Subramanian N, Prajapati VK, Krishnan M; Encapsulation and systemic delivery of 5-fluorouracil conjugated with silkworm pupa derived protein nanoparticles for experimental lymphoma cancer. Bioconjugate Chemistry, 2018 Sep 19;29(9):2994-3009. (IF-6.069)
  48. Pandey RK, Ali M, Ojha R, Prajapati VK*; Development of multi-epitope driven subunit vaccine in secretory and membrane proteins of Plasmodium falciparum to convey protection against malaria infection. Vaccine, 2018 Jul 16;36(30):4555-4565. (IF-4.169)
  49. Pandey RK,Ojha R, Mishra A,Prajapati VK*; Designing B and T cell multi-epitope based subunit vaccine against virulence proteins using immunoinformatics approach to control Zika virus infection. Journal of Cellular Biochemistry; 2018 Sep;119(9):7631-7642. (IF-4.48)
  50. Mishra R, Upadhyay A, Prajapati VK, Mishra A; Proteasome Mediated Proteostasis: Novel Medicinal And Pharmacological Strategies For Diseases. Medicinal Research Reviews, 2018 Sep;38(6):1916-1973. (IF-12.388)
  51. Narula A, Pandey RK, Khatoon N, Mishra A, Prajapati VK*; Excavating chikungunya genome to design B and T cell multi-epitope subunit vaccine using comprehensive immunoinformatics approach to control chikungunya infection. Infection Genetics and Evolution; 2018 July. 61, 4-15 (IF-4.393)
  52. Ojha R, Khatoon N, Prajapati VK*; Conglomeration of Culexquinquefasciatus salivary proteins to devise multi-epitope subunit vaccine against infections caused by blood imbibing transmitter. International Journal of Biological Macromolecules, 2018 Jun 25;118(Pt A):834-843. (IF- 8.025)
  53. Chaterjee N, Ojha R, Khatoon N, Prajapati VK*; Scrutinizing Mycobacterium tuberculosis membrane and secretory proteins to formulate multiepitope subunit vaccine against pulmonary tuberculosis by utilizing Immunoinformatic approaches. International Journal of Biological Macromolecules, 2018 Jun 18;118(Pt A):180-188.  (IF- 8.025)
  54. Veeranarayanan SA, Nattarsingam J, Prajapati VK, Krishnan M; Investigation of immunogenic properties of Hemolin from silkworm, Bombyxmori as carrier protein: an immunoinformatic approach. Scientific Reports; 2018 May 3;8(1):6957. (IF-4.996)
  55. Pandey RK, Sharma D, Ojha R, BhattT, Prajapati VK*; Chemical system biology based molecular interactions to identify inhibitors against Q151M mutant of HIV-1 reverse transcriptase. Infection Genetics and Evolution. 2018 May 9;63:5-12.  (IF-4.393)
  56. Pandey RK, Ojha R, Veeranarayanan SA, Krishnan M, Prajapati VK*;Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection. Vaccine, 2018 Apr 19;36(17):2262-2272. (IF-4.169)
  57. Pandey RK, Prajapati VK*; Molecular and immunological toxic effects of nanoparticles. International Journal of Biological Macromolecules, 2018 Feb;107 (Pt A):1278-1293. (IF- 8.025)
  58. Pandey RK, Bhatt TK, Prajapati VK*; Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by investigating Anopheles Salivary Protein. Scientific Reports; 2018 Jan 18; 8(1):1125. (IF-4.996)
  59. Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VK*; Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Scientific Reports 2017 Aug 23;7(1):9232. (IF-4.996)
  60. Khatoon N, Pandey RK, Prajapati VK*; Exploring Leishmania secretory proteins to design B and T cell multi-epitope vaccine using immunoinformatics approach. Scientific Reports 2017 Aug 15;7(1):8285. (IF-4.996)
  61. Chander S, Pandey RK, Penta A, Choudhary BS, Sharma M, Malik R, Prajapati VK*, Murugesan S; Molecular docking and molecular dynamics simulation based approach to explore the dual inhibitor against HIV-1 reverse transcriptase and Integrase; Combinatorial Chemistry & High Throughput Screening. 2017;20 (8):734-746.  (IF-1.339)
  62. Pandey RK, Narula A, Naskar M, Srivastava S, Verma P, Malik R, Prajapati VK*, Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure based virtual screening and molecular dynamic simulation. Journal of Biomolecular Structure and Dynamics; 2017 Mar;35(4):791-804.(IF-5.235)
  63. Pandey RK, Kumbhar BV, Sundar S, KunwarA, Prajapati VK*; Structure based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogues as potential inhibitor against Leishmania donovanitrypanothione reductase; Journal of Receptors and Signal Transduction; 2017 Feb;37(1):60-70. (IF-2.092)
  64. Ahluwalia PK, Pandey RK, Sehajpal PK, Prajapati VK*; Perturbed miRNA expression by Mycobacterium tuberculosis promotes macrophage polarization leading to pro-survival foam cell. Frontiers in Immunology; 2017 Feb 8;8:107;  (IF- 8.786)
  65. Pandey RK, Kumbhar BV, Srivastava S, Malik R, Sundar S, Kunwar A, Prajapati VK*; Febrifugine analogues as Leishmania donovanitrypanothione reductase inhibitors: binding free energy analysis assisted by ADMET and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics. 2017 Jan;35(1):141-158.(IF-5.235)
  66. Bhardwaj A, Srivastava SK, Khan MA, Prajapati VK, Singh S, Carter JE, Singh AP; Racial disparities in prostate cancer: a molecular perspective. Frontiers in Bioscience (Landmark Ed). 2017 Jan 1;22:772-782. (IF-3.115)
  67. Pandey RK, Prajapati P, Goyal S, Grover A, Prajapati VK*; Molecular Modelling and virtual screening approach to discover potential antileishmanial inhibitors against ornithine decarboxylase. Combinatorial Chemistry & High Throughput Screening. 2016 Dec, 19(10) 813-823(11) (IF-1.339)
  68. Pandey RK, Verma P, Sharma D, Bhatt T, Sundar S, Prajapati VK*, High-throughput virtual screening  and  quantum  mechanics   approach to  develop  imipramine  analogues  as  leads  against trypanothione reductase  of  Leishmania; Biomedicine & Pharmacotherapy; 2016 Oct;83:141-152. (IF-7.419)
  69. Verma P, Pandey RK, Prajapati P and Prajapati VK*; Circulating MicroRNAs: Potential and emerging biomarker for diagnosis of human infectious diseases; Frontiers in Microbiology. 2016 Aug 15;7:1274.  (IF-6.064)
  70. Imamura H, Downing T, Broeck FVD, Sanders MJ, Rijal S, Sundar S, Mannaert A, Vanaerschot M, Berg M, Muylder GD, Dumetz F, Cuypers B, Maes I, Decuypere S, Rai K, Uranw S, Bhattarai NR, Khanal B, Prajapati VK, Sharma S, Stark O, Schoenian G, Koning HD, Settimo L, Vanhollebeke B, Roy S, Ostyn B, Boelaert M, Maes L, Berriman M, Dujardin JC, Cotton JA; Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. Elife. 2016 Mar 22;5. Pii: e12613.(IF-8.14)
  71. Pandey RK, Sundar S and Prajapati VK*; Differential Expression of miRNA Regulates T Cell Differentiation and Plasticity during Visceral Leishmaniasis Infection. Frontiers in Microbiology. 2016 Feb 25;7:206. (IF-6.064)
  72. Pandey RK, Prajapati P, Sharma T, Mandal CC and Prajapati VK*; Epidemiological Investigation of a Jaundice outbreak in Kishangarh, Rajasthan, India, 2014; Journal of Public Health.(2016) 24:83-89. (IF- 2.341)
  73. Pandey RK, Sharma D, Bhatt TK, Sundar S and Prajapati VK*; Developing Imidazole analogues as potential inhibitor for Leishmania donovani Trypanothione reductase: Virtual Screening, Molecular Docking, Dynamics and ADMET approach. Journal of Biomolecular Structure and Dynamics. 2015;33(12):2541-53. (IF-5.235)
  74. Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A. Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study. PloS Neglected Tropical Diseases. 2;9(3), 2015, e0003518. (IF- 4.781) 
  75. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanershchot M, Dujardin JC, Sundar S;In vitro susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis. American Journal of Tropical Medicine & Hygiene, 2013 Oct;89(4):750-4. (IF-2.345)         
  76. Prajapati VK* and Mehrotra S. Advances in the Diagnosis of Visceral Leishmaniasis. Journal of Molecular Biomarker and Diagnosis. 4 (2); 2013, 1000e118.
  77. Hazra S, Ghosh S, Sarma MD S, Sharma S, Das M,Saudagar P, Prajapati VK, Dubey VK, Sundar S, Hazra B; Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. Experimental Parasitology. 2013 Oct;135(2):407-13. (IF- 2.132)
  78. Bhardwaj A, Arora S, Prajapati VK, Singh S, Singh AP. Cancer Stemness- Regulating Micrornas: Role, Mechanisms and Therapeutic Potential; Current Drug Targets. 2013 Sep;14(10):1175-84. (IF- 2.937)
  79. Dayakar A, Chandrasekaran S, Prajapati VK, Veronica TSJR, Sundar S, Maurya R;A rapid method to assess the stage differentiation in Leishmania donovani by flow cytometry. Experimental Parasitology. 2012 Dec;132(4):495-500. . (IF- 2.132)
  80. Prajapati VK, Mehrotra S, Gautam S, Rai M and Sundar S; In VitroAntileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis- Status of Newly Introduced Drugs. American Journal of Tropical Medicine & Hygiene.  2012 Oct;87(4):655-7. (IF-2.345)
  81. Sundar S, Singh A, Rai M, Prajapati VK, Singh A, Ostyn B, Boeleart M, Dujardin JC, Chakravarty J; Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis after a Decade of Use in India. Clinical Infectious Diseases. 2012 Aug; 55 (4): 543-50. (IF-20.999)  (Published as a News in Nature doi:10.1038/nature.2013.12553)
  82. Verma RK, Prajapati VK, Verma GK, Chakraborti D, Sundar S, Rai M, Dubey VK, Singh MS; Molecular   docking and in vitroantileishmanial evaluation of chromene-2-thione analogues.ACS Medicinal Chemistry Letters. 2012 Jan 18;3(3):243-7.(IF- 4.632)
  83. Prajapati VK, Yadav TP, Awasthi K, Rai M, Srivastava ON and Sundar S; An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes is an Effective Treatment for Experimental Visceral Leishmaniasis. Journal of Infectious Diseases, 2012 Jan 15;205(2):333-6.(IF-7.759)
  84. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK,V. Ramesh, Sundar S, Schonian G, Dujardin JC, Salotra P; Drug Susceptibility in Leishmania Isolates following Miltefosine Treatment in cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis. PloS Neglected Tropical Diseases.6 (5), 2012;e1657. (IF- 4.781)
  85. Sundar S and Prajapati VK;Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Current Medicinal Chemistry;19, 36, 2012;3196-3202.    (IF-4.74)
  86. Hazra S, Ghosh S, Debnath S, Seville S, Prajapati VK, Wright CW, Sundar S, Hazra B. Antileishmanial activity of cryptolepine analogues, and apoptotic effects of 2, 7-dibromocryptolepine against Leishmania donovani promastigotes. Parasitology Research.2012 Jul;111(1):195-203.  (IF- 2.383)
  87. Perry M, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian Subcontinent? PloS Neglected Tropical Disease; 5 (9):2011; e1227. (IF- 4.781)
  88. Mukhopadhyay R, Mukherjee R, Mukherjee B, Naskar M, Mandal D, Decupere S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S. Characterisation of antimony resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. International Journal for Parasitology, 41(13-14):2011; 1311-21. (IF- 4.33)
  89. Srivastava P, Prajapati VK, Rai M, Sundar S.An unusual case of Amphotericin B refractoriness in Visceral Leishmaniasis from a non-endemic region of India. Journal of Clinical Microbiology; 49 (8) : 2011; 3088-91.(IF- 11.677)
  90. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S; Targeted killing of Leishmania donovani in vivo and in vitro with Amphotericin B attached to functionalized Carbon Nanotubes; Journal of Antimicrobial Chemotherapy, 2011 Apr;66(4):874-9.  (IF- 5.758)  (Published as research highlight by Nature; doi:10.1038/nindia.2011.74)
  91. Srivastava P, Prajapati VK, Vanaerschot M, Auwera GVD, Dujardin JC, Sundar S. Detection of Leptomonas sp. Parasites in clinical isolates of Kala-azar patients from India. Infection, Genetics and Evolution,10 (7): 2010; 1145-50. (IF- 4.393)
  92. Maurya R, Mehrotra S, Prajapati VK, Nylén S, Sacks D, Sundar S. Evaluation of Blood agar micro-titer plates for culturing Leishmania parasites to titrate the parasite burden in spleen and peripheral blood of VL patients. Journal of Clinical Microbiology. 48(5): 2010; 1932-4.(IF- 11.677)
  93. Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, Nylén S. Human visceral leishmaniasis is not associated with expansion or accumulation Foxp3+ CD4 cells in blood or spleen. Parasite Immunology, 32, 2010, 479–483. (IF- 2.206)
  94. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S.Antileishmanial activity of nano-amphotericin B deoxycholate. Journal of Antimicrobial Chemotherapy, 62(2), 2008:376-80. (IF- 5.758)
Books
  1. System Vaccinology, Editor- Vijay Kumar Prajapati; Paperback ISBN: 9780323859417, Publisher- Elsevier.
Book Chapters
  1. Elora K, Panda M, Prajapati VK* (2023); The Interplay Between Circadian Clock And Viral Infections: A Molecular Perspective. Advances in Protein Chemistry and Structural Biology.Publisher- Elsevier.
  2. Panda M, Kalita E, Rao A, Prajapati VK* (2022); Mechanism of cell cycle regulation and cell proliferation during human viral infection.Advances in Protein Chemistry and Structural Biology.Publisher- Elsevier.
  3. Kalita E, Panda M, Rao A, Prajapati VK* (2022); Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics. Advances in Protein Chemistry and Structural Biology.Publisher- Elsevier.
  4. Sharma V, Singh S, Ratnakar TS, Prajapati VK* (2022); Immunoinformatics and reverse vaccinology methods to design peptide-based vaccines. Book Name- Advances in Protein Molecular and Structural Biology Methods, Pages 477-487.ISBN- 978-0-323-90264-9. Publisher- Elsevier.
  5. Sharma V, Chouhan P, Pandey RK, Prajapati VK* (2021); Recent Therapeutic Strategies for the Treatment of Colon Cancer, Book Name- Colon Cancer Diagnosis and Therapy, Volume 2. ISBN: 978-3-030-64668-4. Publisher- Springer.
  6. Ojha R, Pandey RK, Prajapati VK* (2020) Vaccine delivery systems against tuberculosis. Book Name- Nanotechnology Based Approaches for Tuberculosis Treatment, ISBN: 9780128198117. Publisher- Elsevier.
  7. Pandey R.K., Ojha R., Prajapati VK*.(2020) Wet-Lab Approaches to Determine Three-Dimensional Structures of Proteins.Frontiers in Protein Structure, Function, and Dynamics.Publisher- Springer, Singapore. https://doi.org/10.1007/978-981-15-5530-5_3.
  8. Mandal CC, Mehta J, Prajapati VK; Programmed Death 1 (PD 1)‐Mediated T‐Cell Apoptosis and Cancer Immunotherapy, Apoptosis and Beyond: The Many Ways Cells Die, Sept 2018; ISBN: 9781119432425, Chapterdoi.-10.1002/9781119432463.ch29. Publisher- Wiley Online Library.
  9. Ojha R, Nandani R, Chatterjee N, Prajapati VK*; Emerging role of circular RNA as a potential biomarker for the diagnosis of human diseases. Sept 2018. Advances in Experimental Medicine and Biology.Circular RNA.ISBN- 978-981-13-1425-4.Publisher- Springer Nature.
  10. Prajapati VK* and Pandey RK; Recent advances in the chemotherapy of visceral leishmaniasis. July 2017. Drug Design: Principles and Applications, ISBN : 978-981-10-5186-9; Chapter DOI- 10.1007/978-981-10-5187-6_6. Publisher- Springer Nature.
  11. Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dude A, Shrivastav ON, Sundar S. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach. Advances in Experimental Medicine and Biology. 808: 2014; 77-91.
Tools/Tests

 

Research Guidance

Postdoctoral Guidance-

  1. Dr. Nidhi Gupta, ICMR Young Scientist Fellow (2018-2021)

Ph.D. Thesis/ Research Guidance-

  1. Dr. Rajan Kumar Pandey – Awarded in 2020- Currently working as a Postdoctoral fellow at Karolinska Institute, Sweden
  2. Dr. Rupal Ojha- Awarded in 2022- Currently working as a Postdoctoral fellow at the University of Washington in St’ Louis, USA
  3. Mr. Satyendra Singh- Pursuing
  4. Mr. Ketan Kumar- Pursuing
  5. Mr. Abhishek Rao- Pursuing

 

M.Sc. dissertation guidance for one semester-

1. Mamta Panda (2022)- Nanobody-Peptide-Conjugate (NPC) for Passive Immunotherapy Against SARS-CoV-2 Variants of Concern (VOC)-A Prospective Pan-Corona virus

2. Elora Kalita (2022)- Pharmacognostic evaluation and construction of a neutralizing anti-SARS-COV-2 camillidaeNanobody-drug-conjugate

3. Kiran Gurjar (2021)- Designing of a Multitasking Bispecific Antibody Against Sars-Cov-2 Spike Glycoprotein And Entry Receptors Ace-2 And Dpp4

4. Nidhi Bansal (2021)- High Throughput Virtual Screening and Binding Energy Analysis to develop a single target drug against Spike Protein of B.1.1.7 Lineage of SARS-CoV-2

5. Tadi Sai Ratnakar (2021)- In-silico redesigning of Sarilumab interface residues to enhance IL-6R binding and diminish the IL-6 cytotoxic effects of COVID-19 induced Cytokine release syndrome

6. Vinita Sharma (2020)- Lebrikizumab interface redesigning to improve its therapeutic targeting for IL-13 mediated hyper response

7. Priya Chouhan (2020)- Anti-IL-10 antibody humanization by SDR grafting with enhanced affinity to neutralize the adverse response of interleukin-10

8. Renu Choudhary (2020)- High throughput virtual screening, ADMET Prediction and Binding energy estimation to discover small molecule inhibitors against Immunecheckpoints

9. Aditi Pareek (2019)- Investigation of novel inhibitors for Leishmania donovani trypanothione reductase

10. Tanya Pareek (2019)- In vitro expression and purification of Leishmania donovani trypanothionereducatse

11. Hansa Regar (2019)- Identification of best peptide adjuvant for human toll like receptors: an immunoinformatics approach

12. Nina Chaterjee (2018)- Scrutinizing Mycobacterium tuberculosis membrane and secretory proteins to formulate multiepitope subunit vaccine against pulmonary tuberculosis by utilizing Immunoinformatic approaches

13. Surbhi Dahiya (2018)- Vaccination and immunization strategies to develop Aedesaegypti salivary protein-based subunit vaccine tackling Flavivirus infection

14. Raj Nandini (2018)- Contriving multi-epitope subunit vaccineby exploiting structural and non-structural viral proteins to prevent Epstein Barr Virus associated malignancy

15. Nitesh Upadhyay (2018)- Immunoselective algorithm to devise multi-epitope subunit vaccine fighting against Japenese Encephalitis virus infection

16. Saroj Prajapat (2018)- Salivary Proteins based multi-epitope subunit vaccine erection by utilizing systemic approaches against Culexquinquefasciatus transmitted infections

17. Aruna Narula (2017)- Excavating chikungunya genome to design B and T cell multi-epitope subunit vaccine using comprehensive immunoinformatics approach to control chikungunya infection

18. Mudassar Ali (2017)- Cloning, expression and purification of Leishmania donovanitrypanothione reductase

19. Pooja Kumari (2017)- Computer aided drug discovery approach to design novel inhibitors against tuberculsosis

20. Ajay Bijarniya (2017)- Identification of actinomycetes secreted secondary metabolites as antileishmanial lead by using bioinformatics approach

21. Parmila (2016)- De-novo based distinct identification of non-nucleoside reverse transcriptase inhibitor with improved potency against wild and drug-resistant Q151M strain of HIV-1

22. Geethanjali Vavilapalli (2016)- In silico and in vitro Study: A tug - of - war between Topoisomerase-2 and Novel Drug Methanone to treat Visceral Leishmaniasis

23. Neetu Rathore (2016)- Development of Benzamide As a potential inhibitor against Leishmania donovani topoisomerase –ІІ

24. Mahaveer Nagar (2016)- Molecular modelling, high throughput virtual screening, ADMET and molecular dynamics mechanistic analysis to discover potential antileishmanial inhibitors against L. donovani ornithine decarboxylase

25. Priya (2016)- In silico approaches to develop Quinoline analogues against L. donovanitrypanothione reductase for the treatment of VL infection

26. Avula Kiran (2015)- Role of microRNA in Th1 immunity during visceral leishmaniasis infection

27. Vivek Bajiya (2015)- Role of microRNA in Th2 immunity during visceral leishmaniasis infection

28. Rohit Kumar (2015)- Antileishmanial molecular docking of Chromeneanalogs

29. Manish Singh (2015)- In silico identification of conserved    inverted repeat in leishmania species genome

30. Shailesh Kumar (2015)- Molecular Docking studies ofNitazoxanideanalogs onOrnithine Decarboxylase for Leishmaniasis infection

31. Amrita Kumari (2015)- In silico characterization of synonymous codon usage pattern in human visceral leishmaniasis

32. Harphool K. Verma (2014)- Role of MicroRNAs in the Visceral Leishmaniasis: A Computational Approach

33. Manoj Yadav (2014)- Molecular Docking studies of Febrifugine analogues on Ornithine Decarboxylase for Leishmaniasis infection

34. Lochana Singh (2014)- Molecular Docking studies of Febrifugine analogues on Trypanothione Reductase in Visceral Leishmaniasis infection

35. Nitu Paritosh (2014)- Molecular Docking analysis of Nitroimidazole analogues on Trypanothione Reductase in Visceral Leishmaniasis infection

Conference/ Workshops/Seminars Attended
University Level
 
National
 
International
  • October 2019: Validate workshop and British Society of Immunology conference, London, UK.
    • Jan 2019: Indian Science Congress Association conference at Lovely Professional University
    • December 2018: Association of Microbiologist of India (AMI) conference, Hyderabad.
    • November 2018: School of Advance Sciences in Vaccines; Sao Paulo, Brazil.
    • October 2018: Perspective Technologies in Vaccination and Immunotherapy, Moscow, Russia.
    • January 2018: Indian Society of Chemists & Biologists (ISCB) conference, Jaipur.
    • September 2017: The Biotechnology Research Society of India (BRSI) conference, Nagpur.
    • September 2016: Collaborations in Indian Chemical Ecology, NCBS Bengaluru, India.
    • June 2016: Refresher course in Advances in Life Sciences and Climatic change, Rajkot, Gujarat.
    • June 2015: Sao Paulo School of Advanced Science on Neglected Diseases Drug Discovery focus on Kinetoplastids (SPSAS-ND3); CNPEM Campinas, Brazil.
    • October 2014: ICGEB Leishmania course 2014 at Trieste, Italy.
    • September 2014: Advanced Workshop on Chromosome Structure and Function, Trieste, Italy.
    • February 2014; Young Investigator Meeting (YIM 2014) at Hyderabad, India.
    • Dec 2013 to Jan 2014 (One Month)- Orientation course for teaching organized by JN Vyas University, Jodhpur at Central University of Rajasthan, Ajmer, India.
    • November 2013: ITM-Antwerp Colloquium on infectious diseases, Bangalore, India.
    • October 2013: ICGEB course on Global Infectious Diseases, Cape Town, South Africa.
    • May 2013; Worldleish5- Congress on Leishmaniasis; Brazil.
    • October 2012; CDSA-NIH workshop at New Delhi, India.
    • September 2012; Kaladrug-R workshop and meeting; Kathmandu, Nepal.
    • October 2011; WHO-IRTC Immunology course work, Laussane, Switzerland.
    • June 2011; Nanomedicine Summer School; Wittenberg, Germany.
    • February 2011; ICGEB course work in Trieste, Italy.
    • March 2009; Oral presentation at BHU, Varanasi, India.
    • February 2009; Worldleish4- Congress on Leishmaniasis; Lucknow, India.
    • September 2008; Bio-Rad’s Workshop on Bioplex-Multiplex, Gurgaon, India.
    • December 2007; FACSCalibur Basic Training Course, Gurgaon, India.
Conference/ Workshops/Seminars Organised
University Level
 
National Level
 
International Level

 

Patent Filed/ Published
PATENT FILED
 
 
PATENT PUBLISHED
Citations

Google Scholar h-index- 37, citations- 3870 (On 19th Dec 2022)

(https://scholar.google.com/citations?hl=en&user=3A5_lwYAAAAJ&view_op=li…)